Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
作者信息
Younis N, Soran H, Hassanein M
机构信息
Department of Endocrinology, University Hospital of South Manchester NHS Trust, Manchester.
出版信息
QJM. 2009 Apr;102(4):293-6. doi: 10.1093/qjmed/hcp001. Epub 2009 Jan 15.
PMID:19147659
Abstract
摘要
相似文献
1
Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
QJM. 2009 Apr;102(4):293-6. doi: 10.1093/qjmed/hcp001. Epub 2009 Jan 15.
2
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2011 Mar;13(3):221-8. doi: 10.1111/j.1463-1326.2010.01349.x.
3
Intensive glucose lowering treatment in type 2 diabetes.
BMJ. 2011 Jul 26;343:d4243. doi: 10.1136/bmj.d4243.
4
Interplay of diabetes and coronary heart disease on cardiovascular mortality.
Heart. 2004 Dec;90(12):1371-3. doi: 10.1136/hrt.2004.035766.
5
6
The controversial American University Group Diabetes Study--a look at sulfonylurea and biguanide therapy.
Horm Metab Res Suppl. 1985;15:102-4.
7
Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.
Diabet Med. 2009 Apr;26(4):416-24. doi: 10.1111/j.1464-5491.2009.02696.x.
8
Does lowering of blood glucose improve cardiovascular morbidity and mortality?
Clin J Am Soc Nephrol. 2008 Jan;3(1):163-7. doi: 10.2215/CJN.05041107.
9
Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR.
Postgrad Med. 2012 Sep;124(5):121-35. doi: 10.3810/pgm.2012.09.2598.
10
Glucose-lowering therapy after myocardial infarction: more questions than answers.
Eur Heart J. 2008 Jan;29(2):141-3. doi: 10.1093/eurheartj/ehm595.
Zotero 插件